Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics announced full enrollment of the planned 120 participants in its Phase 2/3 ALSTARS Trial evaluating COYA 302 as a potential treatment for amyotrophic lateral sclerosis. The enrollment milestone does not provide trial efficacy or safety results.

Analysis

Enrollment completion lowers execution risk and makes a clinical readout more schedulable; it does not materially update the probability that COYA 302 works. The key value driver shifts from recruitment to treatment duration, follow-up, endpoint quality, and the timing of database lock and topline results. Those details—and Coya’s cash runway relative to the readout—are not provided, so the catalyst calendar and any financing overhang remain unquantified.

Near term, the announcement may support sentiment, but it is not efficacy evidence and could be a weak basis for a sustained rerating. Over 1–3 months, verify the company’s readout guidance, trial design and endpoints, and cash position. Over 6–18 months, the stock remains exposed to a binary clinical outcome; a positive result could improve partnering leverage, while a miss may sharply impair the program’s value. The contrarian point is that completion of enrollment can be mistaken for clinical de-risking: it removes one operational hurdle, not the central biological uncertainty. Reassess if management delays the expected readout, changes guidance, or reports endpoint or safety concerns.

Key Decisions for Investors

• Do not initiate a directional position solely on the enrollment announcement. Treat it as a timeline update, not a change in clinical odds.
• Before considering a catalyst position, verify the primary endpoint, remaining follow-up, expected database-lock/readout window, and cash runway through that window.
• If already long, size exposure for a binary clinical outcome; avoid adding until the catalyst calendar and financing needs are clearer. A broad biotech hedge such as XBI may reduce sector exposure but will not hedge COYA-specific trial risk.
• Falsify the operational de-risking thesis if management pushes out the readout or discloses material protocol, safety, or retention issues; reassess the investment thesis on topline efficacy and safety data, not enrollment status.